Trial Profile

Nivolumab and chemoradiotherapy for esophageal cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; Cisplatin; Fluorouracil
Indications Adenocarcinoma; Basal cell cancer; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions
Acronyms NOBEL

Most Recent Events

04 Jun 2024 Results(Between January 2019 and September 2021, n=42) studying Effect of nivolumab combined with definitive chemoradiotherapy , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
10 Oct 2021 Status changed from recruiting to active, no longer recruiting.
15 Feb 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com